Nearly 350 companies like Nestle, ABB, Novartis based ... engineered solutions, CEO Erich Schmid, head of economics and external affairs of the Swiss Textiles Bjorn von der Crone and explained ...

A private dinner in a mountainside chalet with the CEO of Novartis? Pourquoi pas ... European Commission President Ursula von der Leyen on Tuesday criticised Chinese trade distortions, while ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

It also saw increased use in China and Japan for hypertension management. In an interview with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto’s U.S. patent expiration ...

The question is: Will the company take it? “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a fourth-quarter earnings call with ...